Sumitomo Pharma Co., Ltd. Logo

Sumitomo Pharma Co., Ltd.

R&D pharma creating medicines for oncology, psychiatry & neurology, focusing on Japan & the US.

4506 | T

Overview

Corporate Details

ISIN(s):
JP3495000006
LEI:
Country:
Japan
Address:
大阪市中央区道修町2丁目6番8号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Sumitomo Pharma Co., Ltd. is a research and development-oriented pharmaceutical company focused on creating innovative medicines and healthcare solutions. The company concentrates its R&D and commercial activities in the therapeutic areas of oncology, psychiatry, and neurology. It develops treatments across various modalities, including small molecules, regenerative medicine, and cell therapy. Sumitomo Pharma operates with global business platforms, with a strategic focus on Japan and the United States as its primary markets. The company's mission is to contribute to the betterment of healthcare and fuller lives for people worldwide by translating scientific innovation into real-world solutions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-04 08:19
Registration Form
確認書
Japanese 8.7 KB
2025-11-04 08:13
Interim Report
半期報告書-第206期(2025/04/01-2025/09/30)
Japanese 319.2 KB
2025-10-31 08:39
M&A Activity
訂正臨時報告書
Japanese 41.0 KB
2025-06-27 09:05
Post-Annual General Meeting Information
臨時報告書
Japanese 29.6 KB
2025-06-26 09:39
Registration Form
確認書
Japanese 8.7 KB
2025-06-26 09:36
Governance Information
内部統制報告書-第205期(2024/04/01-2025/03/31)
Japanese 24.0 KB
2025-06-26 09:31
Annual Report
有価証券報告書-第205期(2024/04/01-2025/03/31)
Japanese 2.1 MB
2025-05-30 09:41
M&A Activity
訂正臨時報告書
Japanese 40.7 KB
2025-05-14 09:18
M&A Activity
訂正臨時報告書
Japanese 36.6 KB
2025-04-28 10:06
Regulatory News Service
訂正臨時報告書
Japanese 24.3 KB
2025-04-28 10:03
Regulatory News Service
臨時報告書
Japanese 19.0 KB
2025-04-03 09:39
M&A Activity
臨時報告書
Japanese 41.7 KB
2025-01-31 08:11
Regulatory News Service
臨時報告書
Japanese 18.7 KB
2024-12-19 07:19
Regulatory News Service
臨時報告書
Japanese 19.2 KB
2024-11-01 03:30
Interim Report
確認書
Japanese 8.7 KB

Automate Your Workflow. Get a real-time feed of all Sumitomo Pharma Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Sumitomo Pharma Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Sumitomo Pharma Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Upstream Bio, Inc. Logo
Developing a monoclonal antibody for severe inflammatory and respiratory diseases.
United States of America
UPB
UroGen Pharma Ltd. Logo
Develops non-surgical therapies for urological cancers using proprietary hydrogel technology.
United States of America
URGN
Valbiotis Logo
Develops clinically tested, plant-based supplements for metabolic & cardiovascular health.
France
ALVAL
Valneva SE Logo
Develops and commercializes vaccines for infectious diseases like chikungunya, Lyme, and Zika.
France
VLA
Vanda Pharmaceuticals Inc. Logo
Develops and commercializes innovative therapies for central nervous system disorders.
United States of America
VNDA
Vaxcell-Bio Therapeutics Logo
Develops CAR-T and CAR-NK immunotherapies for solid tumors and canine lymphoma.
South Korea
323990
Vaxcyte, Inc. Logo
A clinical-stage company developing broad-spectrum vaccines for bacterial infectious diseases.
United States of America
PCVX
VENTURE LIFE GROUP PLC Logo
Develops, manufactures, and distributes consumer self-care products and medical devices globally.
United Kingdom
VLG
Ventyx Biosciences, Inc. Logo
Clinical-stage biopharma developing oral therapies for autoimmune, inflammatory & neuro diseases.
United States of America
VTYX
Verastem, Inc. Logo
Develops cancer medicines targeting the RAS/MAPK pathway, with an approved therapy for ovarian cancer.
United States of America
VSTM

Talk to a Data Expert

Have a question? We'll get back to you promptly.